The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans

British Journal of Clinical Pharmacology

Volumn 46, Issue 6, 1998, Pages 535-539

  Reiche, Christoph ^a   Skodra, Thorsten ^a   Nacke, Axel ^a   Spengler, Ulrich ^a   Sauerbruch, Tilman ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

CYP3A4; Humans; Low dose MEGX test; Monoethylglycinexylidide test; P 450 induction; Rifampicin

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYTOCHROME P450; DEETHYLLIDOCAINE; LIDOCAINE; RIFAMPICIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME INDUCTION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; MALE; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; URINE LEVEL;

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; HUMANS; LIDOCAINE; LIVER FUNCTION TESTS; MALE; MIXED FUNCTION OXYGENASES; REPRODUCIBILITY OF RESULTS; RIFAMPIN;

EID: 0031753154     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00829.x     Document Type: Article

References (28)

1. Bargetzi MJ, Aoyama T, Gonzales FJ, Mcycr UA. Lidocaine metabolism in human liver microsonies by cytochrome P450 III A4. Clin Phannacol Tlicr 1989; 46: 521-527.
2. Imaoka S, Enomoto K, Oda Y, et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsonies: comparison of those with rat hepatic cytochrome P-450s._/ Phannacol Exp Tlicr 1990; 255: 1385-1391.
3. Azoulay D, Lemoine A, Gries JM, et al. Lidocaine metabolite formation in the liver donor as a predictive test for the safe and efficient introduction of cyclosporine in the recipient. Transplant Proc 1993; 25: 2275-2278.
4. Cakaloglu Y, TredgerJM, Devlin J, Williams R. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology 1994; 20: 309-316.
5. Sotaniemi EA, Rautio A, Bäckstrom M, Arvea P, Pelkonen O. CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. BrJ Clin Pharmacol 1995; 39: 71-76.
6. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs, din Phannacol Tlicr 1988; 43: 630-635.
7. CombalbertJ, Fabre I, Fabre G, et al. Metabolism of cyclosporine A: Purification and identification of the rifampin-inducible human liver cytochrome P-450 (cyclosporine A oxidase) as a product of P450IIIA gene subfamily. Dnig Metab Dispos 1989; 17: 197-207.
8. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK 506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753-761.
9. Guengerich FP, Turvey CG. Comparisons of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pliannacol Exp Tlicr 1991; 256: 1189-1194.
10. Li AP, Rasmussen A, Xu L, Kaminski DL. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes.JP/KjniMfo/ Exp Tlicr 1995; 274: 673-677.
11. Nakamoto T, Oda Y, Imaoka S, Funae Y, Fujimori M. Effect of phénobarbital on the pharmacokinetics of lidocaine monoethylglycinexylidide and 3-hydroxylidocaine in the rat: correlation with P450 isoform levels. Drug Metab Dispos 1997; 25: 296-300.
12. Reichel C, Block W, Skodra T, et al. Relationship between cytochrome P-450 induction by rifampicin, hepatic volume and portal blood flow in man. EiirJ Gastromtcrol Hcpatol 1997; 9: 975-979.
13. Block W, Reichel C, Traber F, Skodra T, et al Effect of cytochrome P-450 induction on phosphorus metabolites and proton relaxation times measured by in vivo P-magnctic resonance spectroscopy and H-magnetic resonance relaxometry in human liver. Hepatology 1997; 26: 1587-1591.
14. Reichel C, Nacke A, Sudhop T, et al The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects. Hepatology 1997; 25: 1323-1327.
15. Chen Y, Potter JM, Ravenscroft DJ. A quick, sensitive highperformance liquid chromatography assay for monoethylglycinexylidide and lignocaine in serum/plasma using solid phase extraction. Tlicr Dnig Alonit 1992; 14: 317-321.
16. Transwell P, Koup J. TopFit: a PC-based pharmacokinetic/ pharmacodynamic data analysis program. lut J Clin Plianiiacol Tlicr Toxicol 1993; 31: 514-520.
17. Shah VP, Midha KK, Dighe S, et al Analytical methods validation: unavailability, bioequivalence and pharmacokinetic studies. J Pliann Sei 1992; 81: 309-312.
18. Kuroki S, Naito T, Okamoto S, et al. Cholcstyramine loading test to assess hepatic reserve for bile acid synthesis in patients with chronic liver diseases. Gastrocntcrology 1997; 112: 1277-1283.
19. Oellerich M, Räude E, Durdelski M, et al. Monoethylglycinexylidide formation kinetics. A novel approach to assessment of liver function. J Chcm Clin Biochcm 1987; 25: 845-853.
20. Perucca E, Hedges A, Makki KA, Richens A. A comparative study of antipyrinc and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs. DrJ Clin Pharinaml 1980; 10: 491-497.
21. Oellerich M, Durdelski M, Lautz H-M, Schulz M, Schmidt F-W, Hcrrmann H. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis, liter Drug Monit 1990; 12: 219-226.
22. Rowland M, Thomson PD, Guichard A, Melmon KL. Disposition kinetics of lidocaine in normal subjects. Ann N Y Acad Sei 1971; 179: 383-398.
23. Riem H, Candinas R, Stieger B, Meyer UA, Follath F. Interaction between amiodaron and lidocaine. J Cardiovasc Phannacol 1996; 28: 533-539.
24. Pcrrucca E, Richens A. Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. BrJ Clin Phannacol 1979; 8: 21-31.
25. Ohnhaus EE, Park BK. Measurement of unrinary 6-β-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Phannacol 1979; 15: 1101-1107.
26. GillumJG, Israel DS, Polk RE. Pharmacokinetic.drug interactions with antimicrobial agents. Clin Phannacokinct 1993; 25: 450-482.
27. Wietholtz H, Zysset T, Marschall HU, Generet K, Matern S. The influence of rifampin treatment on caffeine clearance in healthy man. J Hepatol 1995; 22: 78-81.
28. Nakamoto T, Oda Y, Imaoka S, Funae Y, Fujimori M. Effect of phénobarbital on the pharmacokinetics of lidocaine monoethylglycinexylidide and 3-hydroxylidocaine in the rat: correlation with P450 isoform levels. Drug Metab Dispos 1997; 25: 296-300.